Induction and post-remission treatment strategies for a fit, newly diagnosed patient with NPM1/DNMT3A co-mutated AML

During the AML Hub Steering Committee meeting in November 2022, key opinion leaders met to discuss induction and post-remission treatment strategies for fit, newly diagnosed patients with NPM1/DNMT3 co-mutated acute myeloid leukemia (AML).

The recorded discussion was chaired by Lars Bullinger, and featured Uwe Platzbecker, Gunnar Juliusson, Gert Ossenkoppele, and Agnieszka Wierzbowska.

Bullinger begins by outlining the recent changes to the World Health Organization classification of AML, and the International Consensus Classification, as well as the updated risk stratification described in the European LeukemiaNet recommendations. Bullinger goes on to discuss the findings of the HARMONY project, looking at NPM1 mutations within clinically significant co-mutational patterns. The steering committee members then consider how these new data may influence treatment decisions within this patient group and conclude by weighing up the benefits and indications for transplant or the monitoring of minimal residual disease, depending on the nature of the mutations present.